Tekmira to buy OnCore, creating Hepatitis B-focused ‘powerhouse’
January 12, 2015 at 09:56 AM EST
Tekmira Pharmaceuticals agrees to buy OnCore Biopharma, which would create a new company focused on treating hepatitis B that is valued at about $750 million.
